{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-144569","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.650799+00:00","generated_at":"2026-05-15T07:02:03.522225+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026","bullets":["Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.","Milestone triggers $7.5M payment to Cue Biopharma, expected in May 2026.","Collaboration targets differentiated B cell depletion molecules including CUE-501."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-144569","json":"https://secwatch.observer/filing/0001193125-26-144569.json","markdown":"https://secwatch.observer/filing/0001193125-26-144569.md","text":"https://secwatch.observer/filing/0001193125-26-144569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526144569/0001193125-26-144569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526144569/cue-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:02:03.522225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}